The Power of Faze

We’re unique individuals who’ve formed a powerful collective

Our team has come together to harness a new understanding of cellular biology in order to create a new way of treating disease.

Faze’s founders are global leaders in the field of biomolecular condensates who have conducted seminal work within this new scientific discipline. Faze’s leadership team brings together accomplished biotechnology executives with decades of industry experience and deep scientific, drug discovery and drug development knowledge.

Philip Vickers, Ph.D.
Philip Vickers, Ph.D.
President and CEO
Kelly Honohan
Kelly Honohan
Head of Legal and General Counsel
Rachel Meyers, Ph.D.
Rachel Meyers, Ph.D.
Chief Scientific Officer
Jim Hampe
Jim Hampe
Chief Business Officer
Ed Freedman, J.D.
Ed Freedman, J.D.
Chief Financial Officer
Noreen Rizvi, Ph.D.
Noreen Rizvi, Ph.D.
Head of R&D Strategy and Operations
Daryn Lewis
Daryn Lewis
Senior Vice President, Head of People & Culture


Mike Rosen, Ph.D.
Roy Parker, Ph.D.
Ron Vale, Ph.D.
J. Paul Taylor, M.D., Ph.D.

Board of Directors

Cary Pfeffer, M.D.
Chairman of the Board
Philip Vickers, Ph.D.
President and CEO
Bob Tepper, M.D.
Charles Homcy, M.D.
Laura Brass, Ph.D.
Doug Kerr, M.D., Ph.D.
Jim Audia, Ph.D.
Drug Discovery,
Entrepreneur in Residence, Third Rock Ventures
Jesse Cedarbaum, M.D.
Neurology & Translational Medicine,
Adjunct Professor of Neurology and Psychiatry, Yale University School of Medicine
Richard Chesworth, D. Phil
Drug Discovery,
CSO, Kymera Therapeutics
Merit Cudkowicz, M.D.
Neurologist & Clinical Researcher,
Chief, Neurology Department, Massachusetts General Hospital
Julie Forman-Kay, Ph.D.
Biophysics, Disordered Proteins & Computational Tools,
Senior Scientist & Program Head, Molecular Medicine, Hospital for Sick Children
Jason Gestwicki, Ph.D.
Chaperones, Protein Folding, & Small Molecule Drug Discovery,
Professor, Pharmaceutical Chemistry, Weill Institute for Neurosciences, UCSF
Tanja Mittag, Ph.D.
Condensate Biophysics & Structural Biology,
Associate Professor, St. Jude Children's Research Hospital
Craig Muir
Technology & Drug Discovery,
Partner, Third Rock Ventures
Eric Wang, Ph.D.
Myotonic Dystrophy,
Assistant Professor, Molecular Genetics & Microbiology, University of Florida
We’re pioneering a dramatically new way of treating disease

New biological discoveries are exciting, but a key step to translate them into new medicines is the ability to identify a druggable target.

Faze’s technology for target identification is at the forefront of the field. Using a variety of screening and proteomics techniques, we are able to define condensate interaction networks. This map of condensate interactions reveals which protein play a central role in condensate regulation and suggests promising therapeutic targets.

Faze has built an unparalleled product engine to systematically understand and modulate condensates to treat disease:

DISCERN: Identify condensates at the root of a disease, and use a variety of screening and proteomics techniques to define key targets for regulation.

DISRUPT: Leverage proprietary assays to discover small molecules that can alter condensate pathologies, by targeting these key component proteins and regulators.

DEVELOP: Validate small molecules’ effects in proprietary assays and model systems, and advance them through clinical testing.

Our initial therapeutic focus areas are amyotrophic lateral sclerosis (ALS) and myotonic dystrophy type 1 (DM1), and we are also exploring other potential disease categories and indications that may benefit from our approach. A robust body of literature supports the characterization of both ALS and DM1 as diseases of condensate dysregulation.

We’re looking for people to bring about a Faze shift

The potential for Faze’s approach is unlimited. It’s our people who will turn that potential into reality.

If you’re ready to work at the cutting edge of biology and contribute to groundbreaking therapeutics, explore our open jobs below or email us at